Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice

Hepatology Research

Volumn 41, Issue 12, 2011, Pages 1240-1248

  Matono, Tomomitsu ^a   Koda, Masahiko ^a   Tokunaga, Shiho ^a   Kato, Jun ^a   Sugihara, Takaaki ^a   Ueki, Masaru ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Liver fibrosis; Oxidative stress; Steatohepatitis

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA SMOOTH MUSCLE ACTIN; EZETIMIBE; HYDROXYPROLINE; PROCOLLAGEN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; GENE EXPRESSION; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LIVER FIBROSIS; LOW DRUG DOSE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 82255185591     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00888.x     Document Type: Article

References (31)

1. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-98.
2. Jeong WI, Jeong DH, Do SH etal. Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. J Vet Med Sci 2005; 67: 235-42.
3. Mari M, Caballero F, Colell A etal. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006; 4: 185-98.
4. Kainuma M, Fujimoto M, Sekiya N etal. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin resistant fatty liver disease with characteristic fibrosis. J Gastroenterol 2006; 41: 971-80.
5. Wouters K, van Gorp PJ, Beighs V etal. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008; 48: 474-86.
6. Muraoka T, Aoki K, Iwasaki T etal. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. doi:10.1016/j.metabol.2010.06.008.
7. Nozaki Y, Fujita K, Yoneda M etal. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009; 51: 548-56.
8. Grundy SM. Absorption and metabolism of dietary cholesterol. Annu Rev Nutr 1983; 3: 71-96.
9. Altmann SW, Davis HR Jr, Zhu LJ etal. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.
10. Davis Jr HR, Hoos LM, Tezloff G, Maguire M, Zhu LJ, Graziano M. P, wt al. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/-mice. Arte Rioscler Throm Vas Biol 2007; 27: 841-9.
11. Nakagami H, Osako MK, Takami Y etal. Vascular protective effects of ezetimibe in ApoE-dificient mice. Atherosclerosis 2009; 203: 51-8.
12. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 2005; 280: 12710-20.
13. van Heek M, Austin TM, Farley C, Cook JA, Tetzloff GG, Davis HR. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes 2001a; 50: 1330-5.
14. van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001b; 415: 79-84.
15. Davis HR Jr, Zhu LJ, Hoos LM etal. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004; 279: 33586-92.
16. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-19.
17. ob gene. Exp Anim 2010; 59: 407-19.
18. Murawaki Y, Hirayama C. Hepatic collagenolytic cathepsin in patients with chronic liver disease. Clin Chim Acta 1980; 108: 121-8.
19. Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chem Acta 2004; 339: 1-9.
20. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86: 271-8.
21. Zheng S, Hoos L, Cook J etal. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharm 2008; 584: 118-24.
22. Deushi M, Nomura M, Kawakami A etal. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007; 581: 5664-70.
23. Labonte ED, Camarota LM, Rojas JC etal. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am J Physiol Gastrointest Liver Physiol 2008; 295: G776-783.
24. Yagi S, Akaike M, Aihara K etal. Ezetimibe ameliorates metabolic disorders anda microalbuminuriai patients with hypercholesteroloemia. J Atheroscler Thromb 2010; 17: 173-80.
25. Yamauchi T, Kamon J, Ito Y etal. Cloning of receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9.
26. Yamauchi T, Nio Y, Maki T etal. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic action. Nat Med 2007; 13: 332-9.
27. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009; 297: E1030-E1038.
28. Osborne TF. Sterol regulatory element binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem 2000; 275: 32379-82.
29. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.
30. Seki S, Kitada T, Yamada T, Sakaguchi H, Kazuki N, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatology 2002; 37: 56-62.
31. Tous M, Ferre N, Rull A etal. Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. Biochem Biophys Res Commun 2006; 340: 1078-84.